Management and Treatment of Asterixis

Understanding Asterixis

Asterixis is characterized by brief, arrhythmic lapses in sustained posture due to involuntary pauses in muscle contraction, which is a negative myoclonus consisting of loss of postural tone, often present in early to middle stages of hepatic encephalopathy that precede stupor or coma, and can be observed in various body areas including wrists, feet, legs, arms, tongue, and eyelids 1, 2, 3
Asterixis can be elicited by actions requiring postural tone, such as hyperextension of the wrists with separated fingers, and is not actually a tremor 1, 3

The American Association for the Study of Liver Diseases recommends that asterixis can result from various causes, including hepatic encephalopathy, which is the most common cause 1, 4
Asterixis can also be caused by metabolic disorders, such as uremia, hypercapnia, hypoglycemia, and urea cycle defects, as well as electrolyte disturbances like hypokalemia and hypomagnesemia 5
Medication-induced asterixis can occur with antiepileptic drugs, levodopa, opiates, anticholinergics, benzodiazepines, lithium, and clozapine 5

The European Association for the Study of the Liver recommends a diagnostic workup to identify the underlying cause of asterixis, including complete medical history, neurological examination, blood tests, and brain imaging when structural causes are suspected 5, 6
For hepatic encephalopathy, the primary treatment approach includes non-absorbable disaccharides like lactulose to reduce ammonia production, antibiotics like rifaximin to decrease ammonia-producing bacteria, and protein restriction in severe cases 3
The American College of Gastroenterology recommends identification and correction of precipitating factors, such as GI bleeding, infection, and electrolyte disturbances, in patients with hepatic encephalopathy 4

Liver transplantation may be considered in cases of persistent hepatic encephalopathy with prominent extrapyramidal signs, and hepatic myelopathy may reverse with liver transplantation 1, 2, 3
The strength of evidence for these recommendations is based on high-quality studies, with a level of evidence of 1A for the use of lactulose and rifaximin in hepatic encephalopathy 3

The presence of symmetrical neurological findings, myoclonus, lack of fever, acidosis, or unexplained negative base excess suggests non-infectious metabolic causes rather than encephalitis, according to the Journal of Infection 7

No cited facts are available for treatment considerations in the provided article.